Biosimilars Market Size, Share, Trends & Forecast, 2026–2036

Market Definition and Growth Analysis

The biosimilars market comprises biological medicines that have been demonstrated to be highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. In the US, biosimilars are approved through the abbreviated 351(k) pathway established under the Biologics Price Competition and Innovation Act. The market therefore differs from conventional small-molecule generics because biological medicines are complex products manufactured through living systems and require extensive analytical and comparative evidence. The market excludes originator biologics such as Humira and Keytruda, which biosimilars are built to match, and small molecule generics, which follow the ANDA pathway.

The biosimilar medicines market spans FDA and EMA approved products across monoclonal antibodies, TNF-alpha inhibitors, insulins, G-CSF agents, VEGF inhibitors and other biologics. Emerging checkpoint inhibitor candidates and other pipeline products are also considered where relevant to future competitive development. Patent and exclusivity timelines are important to market scope because they influence the timing of biosimilar development, regulatory submissions, and commercial launches.

Key applications include oncology, autoimmune and inflammatory disorders, ophthalmology, diabetes, respiratory and allergic diseases, and other specialty care conditions. Demand in the biosimilar drug market flows through hospital pharmacies, retail pharmacies, specialty pharmacies, pharmacy benefit managers, and online and cash pay platforms. Commercial adoption depends on regulatory approval, interchangeability, payer policy, formulary placement, physician prescribing, pricing and supply.

Drug Pipeline

The biosimilar pipeline is increasingly focused on high-value oncology and ophthalmology biologics. The current pipeline includes multiple programs targeting pembrolizumab, nivolumab, ocrelizumab, pertuzumab, omalizumab, and high-dose aflibercept. Pembrolizumab has multiple disclosed biosimilar programs in clinical development, while aflibercept and other ophthalmology candidates are contributing to competitive activity in specialty biologics. The pipeline analysis is based on disclosed manufacturer information and clinical development activity rather than modeled market projections.

The below table summarizes the most advanced disclosed candidates across oncology and immunology as of mid-2026. The analysis is based on clinical trial registrations and manufacturer disclosures rather than modeled projections.

Drug pipeline analysis

Candidate	Company	Reference Product	Phase	Trial Identifier	Status
SB27	Samsung Bioepis	Keytruda (pembrolizumab) / PD-1 inhibitor	Phase 1/3	Disclosed via company announcement, June 2026	Positive preliminary Phase 1 (PK equivalence) and Phase 3 (equivalent response rate at Week 24) data, 29 June 2026
FYB206	Formycon	Keytruda (pembrolizumab) / PD-1 inhibitor	Phase 1 PK (Dahlia)	Company-disclosed	PK bioequivalence demonstrated, February 2026; a streamlined FDA strategy replaced the Phase 3 trial
ABP 234	Amgen	Keytruda (pembrolizumab) / PD-1 inhibitor	Phase 3	Initiated May 2024, per ClinicalTrials.gov	Recruitment complete; primary completion revised to December 2026
ABP 206	Amgen	Opdivo (nivolumab) / PD-1 inhibitor	Application submitted to FDA	Per ClinicalTrials.gov	Amgen expects a decision by the end of 2026
ABP 692	Amgen	Ocrevus (ocrelizumab) / anti-CD20	Phase 3	Announced at JPM Healthcare Conference, January 2025	Enrolling relapsing-remitting MS patients
EG1206A	EirGenix	Perjeta (pertuzumab) / HER2-directed mAb	Licensed for Japan; PK study complete	Licensing agreement disclosed	Japan licence signed 30 June 2026; FDA and EMA feedback supports an abbreviated pathway
TEV-45779	Teva	Xolair (omalizumab) / anti-IgE	351(k) and EU applications accepted (30 March 2026)	FDA acceptance disclosed	FDA decision expected in Q1 2027
Aflibercept 8 mg biosimilar	Alvotech	Eylea HD (aflibercept, high dose) / VEGF inhibitor	Confirmatory trials	Company-disclosed	Trials underway; company reports early competitive position

Source: Company filings and Polaris Market Research Analysis

Two patterns stand out, PD-1 inhibitors are now the pipeline's center of gravity and Sandoz is building its position through partners, adding Henlius in August 2026 to lift its biosimilar pipeline to 39 assets (Source: fiercepharma.com). Each candidate is measured against a reference biologic whose exclusivity is already dated.

Market Dynamics

Driver: Patent Expiry of High-Revenue Biologics Is Expanding the Biosimilar Pipeline

Patent and exclusivity expiries of high-revenue biologics are creating opportunities for biosimilar manufacturers to develop competing products. This patent cliff is increasing development activity around pembrolizumab, nivolumab, omalizumab, ocrelizumab, and high-dose aflibercept. Projected US exclusivity changes around 2028 for pembrolizumab and nivolumab are encouraging manufacturers to advance clinical programs and prepare future launches. The expansion of this pipeline is generating opportunities in oncology, ophthalmology, autoimmune disorders and other therapeutic areas. More development programs also incentivize manufacturers to build out manufacturing capacity, regulatory capabilities and commercialization plans. Thus, the rising number of biologics approaching patent or exclusivity milestones is driving the growth of the biosimilar market (Source: amgen.com).

Driver: Interchangeability Is Increasing Pharmacy-Level Substitution

Interchangeability is creating opportunities for greater biosimilar uptake by allowing pharmacy level substitution where permitted by applicable laws. Interchangeable biosimilars may be substituted without requiring a new prescriber authorization under applicable state requirements, which can streamline access for patients and pharmacies. The adalimumab class demonstrates this trend, with seven of the eight marketed products reported as interchangeable in the source data. Therefore, manufacturers are incorporating switching studies and interchangeability requirements into development programs. Greater availability of interchangeable products could spur competition and help payers control the costs of biologic treatments. However, adoption is also dependent on pricing, formulary placement, reimbursement, physician prescribing, distribution and product availability in individual markets.

Restraint: Manufacturing Complexity and Rebate Strategies Limit Net-Price Competition

The production of biosimilars demands specialized facilities, the development of cell-lines, analytical characterization, process validation, and comparative evidence, making biosimilar manufacturing more complex than conventional generic production. These requirements increase investment requirements and can make it more difficult for smaller manufacturers to enter the market. Originator rebate strategies can additionally restrict the effective price advantage of biosimilars because of differences in list prices, negotiated prices, and cash-pay prices across purchasing channels. Hence, a lower list price does not necessarily translate into a lower net cost for treatment. Manufacturers have to weigh the costs of production, pricing, regulatory requirements, supply continuity and payer negotiations. These factors can influence the timing of launch, commercial strategies and the ability of new biosimilar entrants to compete effectively.

Opportunity: Oncology Checkpoint Inhibitors Create a High-Value Pipeline

Biosimilar manufacturers are finding opportunities with oncology checkpoint inhibitors as major biologics in this category have large treatment populations and high commercial value. Development activity is underway for pembrolizumab and nivolumab, with several manufacturers advancing biosimilar programs. These candidates can spur competition across high-value oncology biologics as they progress through clinical and regulatory phases. The addressable market can also grow further through indication extrapolation when regulatory requirements are met as an approved biosimilar can address multiple indications of its reference product. This may improve commercial prospects for winning products. Growth in oncology development is also driving manufacturers to build clinical programs, manufacturing capabilities, regulatory expertise and commercialization planning to support future growth of the biosimilar market.

Opportunity: Emerging-Market Manufacturing Partnerships Are Expanding the Addressable Geography

Biosimilar manufacturers are gaining access to markets with a range of regulatory, procurement and distribution requirements through licensing and commercialization partnerships. Local partnerships provide some commercial ability, health care networks and regulatory expertise that manufacturers don’t have to build a whole infrastructure themselves. In June 2026, EirGenix entered into an agreement to commercialize EG1206A, a biosimilar version of pertuzumab, in Japan. Such partnerships can reduce barriers to market entry and help in commercialization with local capabilities. Regional partnerships can also help manufacturers cut development and commercialization costs across markets. As more companies use licensing and commercialization agreements, partnerships can expand the geographic reach of biosimilar products and improve access to biologic therapies in markets seeking cost-containment solutions (Source: eirgenix.com).

Market Segmentation Analysis

The report provides a comprehensive analysis of the biosimilars market by drug class, therapeutic area, interchangeability status, distribution channel, and region to identify key revenue-generating and high-growth segments.

Drug Class Insights

Monoclonal antibodies held approximately 46.18% share of the biosimilars market in 2025, making them the leading drug class. The category benefits from wide commercialization across established products such as adalimumab and ustekinumab. This segment counts monoclonal antibodies other than TNF-alpha and VEGF products, which are reported separately. There are also important opportunities in oncology, autoimmune disease, ophthalmology and other specialty applications. Monoclonal antibodies have a wide clinical application, which offers manufacturers a number of possible indications and commercial opportunities. Further, the development of pembrolizumab, nivolumab, and other antibody-based biosimilars is underway, and is expected to intensify competition in this category during the forecast period.

TNF-alpha inhibitors accounted for an estimated 14.72% share in 2025, owing to the established biosimilar commercialization of these agents in inflammatory and autoimmune indications. The launch of several biosimilars into the US market and the award of interchangeable designations to several products have ensured adalimumab remains a key product category. TNF-alpha inhibitors are used in diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Commercial adoption depends on formulary positioning, pricing, physician prescribing, payer arrangements, and pharmacy access. The category demonstrates how a large number of approved products can create competition while producing different levels of market uptake among individual brands. Continued competition among TNF-alpha inhibitors and other monoclonal antibody biosimilars market is expected to support the segment during the forecast period.

VEGF inhibitors are projected to register the highest CAGR of 8.12% during 2026–2036, supported by growing competition in ophthalmology and multiple aflibercept biosimilar programs. Aflibercept is a key reference product in the category, with Formycon and Klinge, Samsung Bioepis, Sandoz, Celltrion, Biocon and Amgen among the manufacturers with FDA approved biosimilars. The segment is supported by long-term treatment needs for chronic retinal diseases and the potential for additional biosimilar entrants. Regulatory approvals and commercial launches can increase treatment options and competitive pressures. High-dose aflibercept biosimilars also highlight manufacturers’ ongoing interest in ophthalmology biologics.

Insulins accounted for 11.36% of the biosimilars market in 2025. Insulin biosimilars serve chronic diabetes care and depend on payer coverage and pharmacy level substitution. G-CSF agents accounted for 9.84% share in 2025. ENNUMO became the eighth US pegfilgrastim biosimilar in May 2026, adding price pressure in supportive oncology care (Source:gabionline.net).

The others (Growth Hormone, Erythropoietin) segment accounted for 9.14% share in 2025. The categories are at various stages of commercial development. G-CSF biosimilars are well established in supportive oncology care and insulin biosimilars are used for chronic diabetes. The competitive landscape is different for different regulatory pathways, prescribed behaviors, reimbursement structures, manufacturing requirements, and economics of reference products. This large number of categories allows product manufacturers to have different commercial strategies for the chronic care market and the specialty care market. The expansion of approvals and increased acceptance by payers and providers are likely to bring in additional adoption during the forecast period.

Therapeutic Area Insights

Autoimmune and inflammatory disorders held approximately 35.27% share in 2025. This segment is backed by established biosimilar activity across adalimumab and ustekinumab. Major indications include psoriasis, rheumatoid arthritis, inflammatory bowel disease and other chronic inflammatory conditions. Past patent and exclusivity changes for major biologics have created openings for biosimilar entrants. The segment also benefits from recurring treatment requirements which can support sustained demand for biologics therapies. The commercial uptake varies across countries and payer systems due to the impact of reimbursement policies, formulary placement, substitution rules, physician prescribing, and negotiated pricing on product utilization. Price competition among adalimumab, ustekinumab and infliximab biosimilars decides how much share converts into net revenue.

Oncology accounted for approximately 38.64% share in 2025 and is expected to register a CAGR of 8.36% during 2026 to 2036. The pipeline is now moving beyond established trastuzumab biosimilars to PD-1 inhibitors, where nivolumab and pembrolizumab programs are in late stage development or under FDA review.

Diabetes mellitus accounted for 7.62% share in 2025. Insulin aspart and glargine biosimilars are the main products, and substitution at the pharmacy is where biosimilar savings show up most directly.

Ophthalmology accounted for approximately 9.83% share in 2025 and is expected to register a CAGR of 7.72% from 2026 to 2036. The segment includes aflibercept and ranibizumab biosimilars used for chronic eye conditions. Development activity around aflibercept is increasing the competitive pipeline. Repeat demand can be created by long-term treatment requirements and more product choices may be available to healthcare providers with additional biosimilar entrants. Commercial performance is still being affected by regulatory approvals, physician adoption, reimbursement arrangements, procurement structures and product availability. The development of high-dose aflibercept biosimilars adds another area of pipeline activity in ophthalmology and can broaden future competition.

Others, which includes respiratory and allergic diseases accounted for around 8.64% share in 2025. The biosimilar opportunity in this therapeutic area is expanding with development activity around omalizumab. Potential competition for established biologic therapies used in allergic and respiratory conditions is coming from FDA review activity and manufacturer programs. The category is still less crowded than some of the established oncology and autoimmune segments, so there is room for more manufacturers to develop and commercialize biosimilars. Product approvals, clinical evidence, interchangeability issues and access to reimbursement will influence future uptake. The emergence of omalizumab biosimilars additionally emphasizes the broader growth of biosimilar competition outside the traditional oncology and autoimmune spaces.

Interchangeability Status Insights

Non-interchangeable biosimilars accounted for approximately 71.36% share in 2025, which is the largest category. This segment also includes approved biosimilars without an interchangeable designation. Adoption factors include pricing, formulary placement, physician prescribing, payer policies, product availability and distribution. Such products may still be widely used through the usual channels of prescribing and institutional procurement, although substitution at the pharmacy level may vary. Manufacturers are still assessing the commercial value of interchangeability in terms of development needs, market access conditions, and potential for substitution.

Interchangeable biosimilars are projected to register the highest CAGR of 8.92% from 2026–2036. Growth is supported by pharmacy-level substitution opportunities where permitted by applicable laws. The expanding FDA-approved interchangeable pool is increasing manufacturer interest in the designation. Adalimumab provides an important example, with seven of eight marketed products reported as interchangeable. Growth is supported by pharmacy level substitution where state law permits. The pool of interchangeable products is expanding, and adalimumab is the molecule where the designation matters most. Uptake depends on cost, payer policy, formulary listing and prescribing practice, so interchangeable status widens access without setting share.

Adalimumab biosimilars held about 61.35% share of the interchangeable biosimilars segment in 2025 and are anticipated to expand rapidly during the forecast period from 2026 to 2036. Seven of eight products on the market were said to be interchangeable, pointing to the increasing role of substitutions at the pharmacy level. But pricing, formulary placement, physician prescribing, payer policies, and access to distribution all influence adoption. Further competition could enhance product availability and substitution opportunities.

The checkpoint inhibitor and omalizumab biosimilars are expected to register a CAGR of 10.63% during the forecast period of 2026-2036, driven by increased development activities in oncology and respiratory applications. These emerging products can expand the future biosimilar pipeline and add additional competition to high-value biologics. More and more manufacturers are looking at interchangeability requirements earlier in development which can aid future substitution opportunities The increasing development activity may also increase the demand for switching studies and regulatory strategies.

Distribution Channel Insights

In 2025, hospital pharmacies had the biggest market share, accounting for around 58.37%. Infused biosimilars used in oncology and other clinical settings help to fuel the segment. Hospital distribution is supported by institutional purchasing, centralized procurement, formulary management and supervised administration. Hospitals and oncology buying groups assess products on price, clinical coverage, continuity of supply, and contracting terms. The channel is still important for biologics that need to be administered by healthcare professionals and require controlled handling. Hospital and oncology buying groups contract on price, clinical coverage and continuity of supply, and each new approval gives them another product to contract against.

Retail and specialty pharmacies together accounted for 34.21% share in 2025 and are expected to grow significantly during the forecast period from 2026 to 2036. Boehringer Ingelheim's GoodRx offer put an unbranded adalimumab biosimilar at more than 70,000 US retail pharmacies at $550 per two pack (Source: prnewswire.com). Specialty pharmacies provide patient education, cold-chain logistics, adherence programs, delivery and reimbursement services to support biologics. Eligible self-administered products, including some adalimumab and insulin biosimilars, are available at retail pharmacies. Pharmacy-level substitution where allowed can be supported by wider availability of interchangeable products. As biosimilar use expands, growth will hinge on payer arrangements, substitution rules, product availability, specialty networks and patient demand.

Online and cash-pay platforms had an 7.42% market share in 2025 and are expected to exhibit a CAGR of 9.26% from 2026 to 2036. These platforms provide alternative purchasing routes for selected self-injectable biosimilars and can improve price transparency. Their potential is strongest for products suitable for home administration. Growth is driven by regulatory requirements, prescription process, reimbursement, product availability, cold chain capabilities and patient acceptance. Digital purchasing can augment traditional pharmacy channels by providing additional access and fulfillment options for select biosimilar therapies.

Regional Insights

North America Biosimilars Market Trends

North America was the leading regional market in 2025, with a share of about 34.68% of the global biosimilars market. The region has active FDA approval activity, more interchangeable biosimilars use, established specialty pharmacy infrastructure, and mature payer and formulary systems. In July 2026, Accord BioPharma announced FDA approval of ENNUMO, its second pegfilgrastim biosimilar, which the FDA approved on 7 May 2026, and Accord now offers ENNUMO, UDENYCA and FILKRI (Source: goodwinlaw.com). The US and Canada have separate pricing and procurement schemes. US biosimilar use is influenced by rebates, formulary placement, pharmacy substitution and payer arrangements, and Canada's public procurement follows a separate model from US rebate driven contracting.

Europe Biosimilars Market Trends

Europe accounted for approximately 31.54% of the biosimilars market in 2025, supported by a regulatory system that has approved biosimilars for two decades and long experience with tender based procurement. Teva announced on 4 June 2026 that its aflibercept biosimilar AHZANTIVE reached patients in France, Germany, Spain and the Netherlands from May 2026, with more launches planned this year (Source: globenewswire.com). Country level procurement, pricing and reimbursement rules still shape uptake.

Asia Pacific Biosimilars Market Trends

Asia Pacific is projected to register the highest CAGR of 8.47% during 2026–2036. Growth is supported by rising oncology demand, healthcare cost pressures, expanding biologics manufacturing capabilities, and increasing development activity in China, South Korea, and India. On 17 August 2026, Henlius and Sandoz agreed a collaboration on up to 10 mAb and ADC biosimilars, worth up to USD 322 million (Source: biospace.com). Regional manufacturers are ramping up activity in high-value biologics, while companies such as Samsung Bioepis, Celltrion and Biocon Biologics continue to develop or commercialize biosimilar products. Additionally, the region is also witnessing increasing domestic manufacturing capabilities and demand for cost-effective biologic treatments.

Latin America Biosimilars Market Trends

Latin America accounted for around 4.11% of the global biosimilar medicines market in 2025. The region is developing around oncology, autoimmune therapies and selected rare disease applications as healthcare systems look for alternatives to high cost originator biologics. Brazil and Argentina are important markets due to their healthcare infrastructure and growing biosimilar activity. In 2025, Argentina approved a biosimilar agalsidase beta for Fabry disease, an early example of rare disease activity. Key to future growth are regulations, government procurement, reimbursement, local manufacturing capabilities, pricing and availability. Manufacturers may also use regional licensing and distribution partnerships to address differences in regulatory and commercial requirements across individual Latin American markets (Source: gabionline.net).

Middle East and Africa Biosimilars Market Trends

Middle East & Africa is projected to register a CAGR of 7.56% during the forecast period. On 17 September 2026, Shilpa Biologicals signed an exclusive licence with Saudi Arabia's SPIMACO Bio for PD-1 inhibitor biosimilars across MENA, with a phased technology transfer meant to build local manufacturing in Saudi Arabia and support Vision 2030 localization goals (Source: pharmasource.global). The region remains at an earlier stage of biosimilar adoption, with oncology and autoimmune therapies representing important applications through hospital procurement. Saudi Arabia and the UAE are key markets because of healthcare investment programs and ongoing development of advanced healthcare infrastructure. Licensing and commercialization partnerships are becoming relevant market-entry mechanisms because local regulatory knowledge, distribution capabilities, and healthcare relationships can support commercialization. Regional adoption will also depend on government procurement policies, reimbursement, physician acceptance, pricing, and supply continuity. Partnerships between international manufacturers and local organizations can help address these market-entry requirements and expand the availability of biosimilar medicines across the region.

Biosimilars Market Competitive Landscape

The biosimilars market is consolidating around manufacturers with strong regulatory, clinical, and manufacturing capabilities, while regional players continue to target individual molecules. Boehringer Ingelheim (Cyltezo), Teva (Simlandi, marketed for Alvotech) and Fresenius Kabi (Idacio) compete in adalimumab, and Accord BioPharma has built a pegfilgrastim and filgrastim portfolio.

Interchangeability and payer access are becoming critical drivers of commercial performance. An interchangeable designation and preferred formulary placement for adalimumab can improve substitution at the pharmacy level and patient access. Samsung Bioepis, Formycon, Amgen and Bio-Thera are all advancing their pembrolizumab programs, highlighting the significance of indication coverage and regulatory advancement.

Biosimilars Market: Competitive Positioning Snapshot

Company	HQ	Business Model	Geographic Stronghold	Positioning
Sandoz International GmbH	Switzerland	Pure play generics and biosimilars, independent since the 2023 spin off	Europe strongest; strong US and global reach	Leader: broadest multi class portfolio and the largest dedicated biosimilar footprint
Amgen Inc.	United States	Originator biologics company with an in house biosimilar arm	United States; expanding in Europe	Leader in US oncology and inflammation biosimilars
Pfizer Inc.	United States	Diversified pharma with an established biosimilar portfolio from the Hospira legacy	United States and Europe	Mid tier incumbent: biosimilars are a side business, not a growth priority
Celltrion Inc.	South Korea	Integrated biosimilar developer and manufacturer with direct commercial operations	Europe, US, Asia Pacific	Leader: among the fastest growing dedicated biosimilar companies
Samsung Bioepis Co., Ltd.	South Korea	Development focused biosimilar company using commercial partners	US and Europe via partners	Leader or strong challenger: deep pipeline including oncology and ophthalmology
Biocon Biologics Ltd.	India	Integrated biosimilar company, expanded through the Viatris biosimilars acquisition	US, Europe, emerging markets	Leader among Asian players: strong oncology and diabetes franchises
Fresenius Kabi	Germany	Diversified hospital products company with a growing biosimilar unit	Europe and US	Challenger: biosimilars built on its hospital channel relationships
Alvotech SA	Iceland	Pure play biosimilar developer and manufacturer; partners handle commercialization	Europe; US via partners such as Teva	Challenger: strong pipeline and vertically integrated manufacturing
Teva Pharmaceutical Industries Ltd.	Israel	Generics major commercializing partnered biosimilars	US and Europe	Challenger: distribution and channel strength rather than in house development
Boehringer Ingelheim	Germany	Originator pharma with a narrow biosimilar presence	US and Europe	Niche: adalimumab focused
Accord BioPharma	United States	US specialty arm of Intas; licenses and acquires biosimilars	United States	Challenger in the US: rapidly consolidating assets
Formycon AG	Germany	Development focused biosimilar company with licensing partners	Europe; US via partners	Niche to challenger: ophthalmology and immunology pipeline
Shanghai Henlius Biotech, Inc.	China	Biologics developer with global out licensing	China; Europe and US via partners	Challenger: leading Chinese biosimilar developer
Dr. Reddy's Laboratories Ltd.	India	Generics major building a biosimilar portfolio	India and emerging markets; expanding in regulated markets	Niche to mid tier

Source: Company filings and Polaris Market Research Analysis

Technology and Innovation Landscape

Three technology shifts are reshaping how biosimilars are built and sold:

• Integrated platforms: Henlius handles development, manufacturing and supply of its Sandoz programs through its own biologics platform (Source:pharmexec.com).
• Lighter clinical requirements: EirGenix reported FDA and EMA feedback supporting an abbreviated pathway for EG1206A, including a possible waiver of Phase 3 comparative efficacy trials (Source: pharmaindustrial-india.com).
• Delivery formats: Sandoz holds an option on Henlius's recombinant human hyaluronidase to develop a subcutaneously administered biosimilar (Source: europeanpharmaceuticalreview.com). Biosimilar manufacturing capacity now matters as much as trial data.

Biosimilars Market Buyer Analysis

Biosimilar purchasing involves hospital systems, oncology group purchasing organizations, pharmacy benefit managers, cash-pay patients, and specialty pharmacies. Each buyer group evaluates price, formulary access, interchangeability, indication coverage, delivery requirements, and patient services.

Buyer Decision Framework

Buyer Persona	Primary Driver	Typical Purchasing Consideration
Hospital / Oncology GPO	Net price and clinical coverage	Multi-indication contracting
Pharmacy Benefit Manager	Rebate and formulary position	Tier placement
Cash-Pay Patient	Price and access	Discount platform availability
Specialty Pharmacy	Adherence and delivery	Device and cold-chain requirements

Source: Polaris Market Research Analysis

Barriers to Market Entry

• Manufacturing investments: Biologics need dedicated facilities, cell lines and process validation. That fixed cost is why smaller developers partner or exit.
• Clinical development costs: Comparative studies add time and cost. Regulators can waive Phase 3 efficacy trials case by case.
• Existing IP and litigation risk: Keytruda's compound patent expires in December 2028, but further patents run to 2029 and are expected to be litigated.
• Formulary access: Rebates can favor higher priced products, so a lower list price alone does not win share.
• Indication extrapolation: Oncology developers must satisfy regulators for each claimed indication.
• Supply chain risk: Importing from abroad can bring risks related to tariffs and logistics.

Biosimilars Market Premium Insights and Forward Outlook

Checkpoint Inhibitor Biosimilars Will Define the Next Competitive Cycle

Pembrolizumab and nivolumab represent major opportunities in the next biosimilar development cycle due to their large oncology applications and projected 2028 exclusivity changes. Multiple manufacturers are advancing comparative programs, while extrapolation of indications can expand the addressable patient population when regulatory requirements are met.

The period before projected exclusivity changes provides manufacturers and buyers an opportunity to evaluate pipeline candidates, regulatory progress, indication coverage, and potential access strategies. Commercial position will follow clinical progress, approvals, pricing and formulary access as programs near launch.

Interchangeability Is Increasingly Important for Commercial Adoption

Approval volume alone does not determine commercial uptake across biosimilar categories. The adalimumab market demonstrates differences in product adoption despite a large number of approved biosimilars. Product utilization could be affected by interchangeability designation, biosimilar switching study requirements, formulary position, price, distribution, and prescriber uptake.

Therefore, manufacturers are focusing more on interchangeability studies and payer engagement during product development. Combining a strong comparative data package with formulary substitution planning and distribution capabilities can improve commercial readiness when a biosimilar reaches the market.

Cost and Pricing Benchmarking Analysis

Pricing differs significantly across molecules and distribution channels. Adalimumab provides the most transparent publicly visible discount benchmark, whereas oncology and ophthalmology products generally correspond to institutional procurement and reimbursement arrangements. These differences create varied biosimilar savings opportunities across therapeutic categories and purchasing channels.

Pricing Analysis

Product	Reference Product Price	Biosimilar Price	Indicative Discount
Adalimumab-adbm, unbranded	Humira: $6,922. per carton	$550 per two-pack carton	~92%
Adalimumab-adbm, GoodRx listing	Average retail: $1,705.82	$550	~68%
Adalimumab-aqvh, Yusimry	Humira: $6,922 per carton	$639 at launch	~85%
Hadlima	Humira: $6,922 per month	~$929 per prescription	~87%

Source: Pricing sources and Polaris Market Research Analysis.

Key Players in the Biosimilars Market

• Accord BioPharma Inc.
• Alvotech S.A.
• Amgen Inc.
• Amneal Pharmaceuticals, Inc.
• Biocon Biologics Ltd.
• Bio-Thera Solutions, Ltd.
• Boehringer Ingelheim International GmbH
• Celltrion, Inc.
• Dr. Reddy's Laboratories Ltd.
• EirGenix, Inc.
• Formycon AG
• Fresenius Kabi AG
• mAbxience Holdings S.L.
• Organon & Co.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Group AG
• Shanghai Henlius Biotech, Inc.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited

Industry Developments

• 17 September 2026: Shilpa Biologicals signed an exclusive licence with SPIMACO Bio for PD-1 inhibitor biosimilars across MENA (Source: chemindigest.com).
• 8 September 2026: Bristol Myers Squibb and Ono filed a BPCIA suit against Amgen over its nivolumab biosimilar ABP 206, asserting seven patents (Source: bigmoleculewatch.com).
• 17 August 2026: Henlius granted Sandoz exclusive rights outside China to up to 10 mAb and ADC biosimilars, with payments of up to USD 322 million (Source: henlius.com).
• 9 July 2026: Accord BioPharma announced FDA approval of ENNUMO, its second pegfilgrastim biosimilar (Source: prnewswire.com).
• 1 July 2026: Celltrion launched an autoinjector formulation of Omlyclo in Korea (Source: pearceip.law).
• 30 June 2026: EirGenix signed a Japan licensing agreement for EG1206A (Source: geneonline.com).
• 29 June 2026: Samsung Bioepis reported positive preliminary Phase 1 and Phase 3 data for SB27 (Source: biospace.com).
• 4 June 2026: Teva announced the European launch of AHZANTIVE, which began in May 2026 (Source: goodwinlaw.com).
• 30 March 2026: The FDA and EMA accepted Teva's omalizumab biosimilar filings, with an FDA decision expected in Q1 2027 (Source: biosimilarsrr.com).
• 25 February 2026: Formycon and Zydus reported that the Phase 1 Dahlia PK study met its primary objective, demonstrating bioequivalence of FYB206 and Keytruda (Source: formycon.com).

Biosimilars Market Report Segmentation

By Drug Class Outlook (Revenue, USD Billion, 2021–2036)

• Monoclonal Antibodies
• TNF-Alpha Inhibitors
• Insulins
• Granulocyte Colony-Stimulating Factor (G-CSF) Agents
• VEGF Inhibitors
• Others

By Therapeutic Area Outlook (Revenue, USD Billion, 2021–2036)

• Autoimmune and Inflammatory Disorders
• Oncology
• Ophthalmology
• Diabetes Mellitus
• Others

By Interchangeability Status Outlook (Revenue, USD Billion, 2021–2036)

• Interchangeable Biosimilars
  • Adalimumab biosimilars
  • Checkpoint Inhibitor and Omalizumab Biosimilars
• Non-Interchangeable Biosimilars

By Distribution Channel Outlook (Revenue, USD Billion, 2021–2036)

• Hospital Pharmacies
• Retail and Specialty Pharmacies
• Online / Cash-Pay Platforms

By Regional Outlook (Revenue, USD Billion, 2021–2036)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa

Biosimilars Market Report Scope

Report Attributes	Details
Market Size in 2025	USD 35.22 Billion
Market Size in 2026	USD 37.54 Billion
Revenue Forecast by 2036	USD 73.24 Billion
CAGR	6.9% from 2026–2036
Base Year	2025
Historical Data	2021–2024
Forecast Period	2026–2036
Quantitative Units	Revenue in USD Billion and CAGR
Report Coverage	Revenue Forecast, Growth Factors, Competitive Landscape, Industry Trends, and Strategic Analysis
Segments Covered	By Drug Class By Therapeutic Area By Interchangeability Status By Distribution Channel
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Competitive Landscape	Company Profiling, Product Benchmarking, Financial Analysis, Market Developments, and Strategic Initiatives
Report Format	PDF + Excel
Customization	Available by Country, Region, and Segment

Source: Polaris Market Research Analysis

Why Choose Polaris Market Research

Polaris Market Research & Consulting, Inc. builds this biosimilars market analysis on regulatory disclosures, clinical trial registrations, manufacturer filings and pricing databases, so the pipeline and pricing sections cite named products and dated announcements, not modeled ranges alone.

This biosimilars market report tracks interchangeability as its own segmentation variable, which most syndicated reports fold into drug class or leave out. It is now one of the clearest signals of which biosimilar turns approval into formulary share. Clients evaluating a specific therapeutic area, region or buyer segment can request a tailored scope review to align the segmentation with their commercial focus.

Biosimilars Market Research Methodology

The biosimilars market size and forecast in this report follow the Polaris Market Research & Consulting, Inc. research methodology. It combines secondary research, primary validation, top down and bottom up estimation, and triangulation. The approach is adapted to a market where FDA biosimilar approval, patent expiry timing, interchangeability and pricing decide commercial outcomes.

Project Setup and Scope

Each project starts with the client objective and a defined market scope. For this biosimilar drugs market study, the scope covers biosimilars licensed by the FDA and EMA and excludes originator biologics and small molecule generics. Segments are aligned by drug class, therapeutic area, interchangeability status, distribution channel and region. The historical period is 2020 to 2024, with 2025 as the base year and 2026 to 2036 as the forecast period.

Data Collection

Secondary research forms the foundation. Polaris reviews 50 to 100 or more sources per project, which supply roughly 60 to 80% of total data inputs. For biosimilars these include:

• FDA Purple Book records and EMA public assessment reports
• ClinicalTrials.gov registrations
• Company filings such as 10-Ks and annual reports
• Manufacturer press releases and investor presentations
• Patent expiry and litigation disclosures
• Wholesale acquisition cost lists and GoodRx and Drugs.com pricing information
• Trade publications that track approvals, launches and deals

Primary validation then tests these findings through interviews with manufacturers, distributors and channel partners, and industry experts and consultants, with attention to formulary and pharmacy buying practice. Polaris standards call for 25 to 40 interviews, carrying 30 to 40% of the validation weight.

Data Structuring

All inputs are standardized into one format and segmented by drug class, therapeutic area, interchangeability status, distribution channel and region. Values are converted to common units (USD Mn and Bn), and volume and pricing are aligned wherever revenue must be estimated. Overlaps are reviewed and assigned to a single segment so nothing is counted twice. One example is a monoclonal antibody that is also a TNF-alpha or VEGF inhibitor. Variance between sources is held under 5%.

Market Estimation

Two methods are run in parallel.

• Top down: the estimate starts from the reference biologic revenue pool that biosimilars address. It is then narrowed to the report scope, and biosimilar penetration by molecule is applied. The result is split by segment and region.
• Bottom up: the estimate starts from company level revenue for leading biosimilar manufacturers such as Amgen, Sandoz, Pfizer, Celltrion, Samsung Bioepis, Biocon Biologics and Teva. Polaris standards call for data from 20 to 25 companies. Revenue is mapped to segments and aggregated, and gaps are filled with industry benchmarks.

Both methods are reconciled within a 5 to 10% variance check before the final market figure is set.

Forecasting

Forecasts blend historical patterns with real time market validation. Analysts examine multi year growth rates, pricing movement, and the balance of supply and demand. The main assumptions are patent expiry timing, FDA biosimilar approval activity, interchangeable designations, net price erosion and formulary substitution. Regulatory changes and regional manufacturing capacity are also weighed. Industry inputs are used to check every growth assumption before it is applied to a segment or region.

Validation and Quality Check

Estimates are triangulated across three sources: company level data, primary inputs from industry participants, and secondary benchmarks. Variance is kept within 5 to 10%, and adjustments are applied to align the estimates. Quality checks confirm that segment totals equal 100%, regional estimates reconcile to the global figure, and historical trends support the forecast.

Output and Delivery

The final outputs are market size estimates in USD Mn and Bn, segment distribution in percent, and CAGR. They are delivered as tables, charts, segment level datasets and Excel files. Custom data cuts and post delivery analyst support are available, and Polaris tracks market developments after delivery to keep the data current.

This report was researched by the pharmaceuticals research team at Polaris Market Research & Consulting, Inc. and reviewed by Prajakta Bengale, Research Manager before publication. Market sizing uses proprietary Polaris methodology and does not rely on third party syndicated estimates. Clients who want the sizing and forecast method walked through can speak with a Polaris analyst before making a formulary, pipeline or competitive positioning decision.

Research Methodology Overview

Research Phase	Key Activities	Data Sources and Inputs	Control Measure
Project Setup	Define scope, segments, regions and timeline	Client objective, FDA and EMA scope definitions	Base year 2025, forecast 2026 to 2036
Data Collection	Secondary review, then primary validation	Purple Book, EMA reports, ClinicalTrials.gov, company filings, pricing lists; interviews with manufacturers, channel partners and experts	30 to 50+ sources; 18 to 30 interviews
Data Structuring	Standardize, segment and align units	Drug class, therapeutic area, interchangeability, distribution channel, region	Variance under 5%
Top Down Estimation	Reference biologic pool, scope alignment, penetration by molecule	Reference biologic revenues, biosimilar uptake data	5 to 10% reconciliation check
Bottom Up Estimation	Company level revenue mapped to segments	Leading biosimilar manufacturer financials	12 to 20 companies; 60 to 80% coverage
Forecasting	Trend analysis with driver and restraint assumptions	Approvals, patent expiries, interchangeability, pricing, regulation	Expert validation of growth assumptions
Data Validation	Triangulate company, primary and secondary data	Cross checked datasets	Variance within 5 to 10%; segments total 100%
Output and Delivery	Final tables, charts and datasets	Market size, segment share, CAGR	Excel files and analyst support

Source: Polaris Market Research & Consulting, Inc. Analysis